Fineline Cube

Follow:
14398 Articles
Shanghai Henlius and Organon Submit Biosimilar Application for Denosumab to FDA
CompanyDrug

Shanghai Henlius and Organon Submit Biosimilar Application for Denosumab to FDA

Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion
Company

Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion

AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV
CompanyDrug

AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV

Acotec Secures NMPA Approval for Acotrace Disposable Catheter Sheath
CompanyMedical Device

Acotec Secures NMPA Approval for Acotrace Disposable Catheter Sheath

Innovent's Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%
CompanyDeals

Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System
CompanyMedical Device

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients
CompanyDrug

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions
CompanyDeals

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges
CompanyMedical Device

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards
Company

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards

Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases
CompanyDeals

Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases

Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer
CompanyDrug

Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer